Navigating 21 CFR Part 820: Compliance and Requirements for Medical Device Manufacturers
Overview: Navigating 21 CFR Part 820 Compliance
21 CFR Part 820, issued by the U.S. Food and Drug Administration (FDA), sets forth the Current Good Manufacturing Practice (CGMP) regulations required for medical device manufacturers selling finished devices in the United States. Under the FDA’s modernized Quality Management System Regulation (QMSR) framework, 21 CFR Part 820 incorporates ISO 13485:2016 by reference, establishing global quality management system (QMS) requirements covering management responsibility, design controls, document controls, purchasing controls, CAPA, and recordkeeping. Compliance ensures that medical devices consistently meet safety, efficacy, and regulatory performance criteria throughout their product lifecycle.
Contact us
Introduction to FDA 21 CFR Part 820
Entering and retaining access to the U.S. healthcare market requires rigorous adherence to federal regulations enforced by the U.S. Food and Drug Administration (FDA). For medical device companies, establishing a compliant quality system is governed by 21 CFR Part 820, historically known as the Quality System Regulation (QSR).
Whether your organization produces Class I, Class II, or Class III finished devices, understanding Navigating 21 CFR Part 820: Compliance and Requirements for Medical Device Manufacturers is vital. It outlines the mandatory operational standards—from engineering design to post-market complaint tracking—needed to prevent product recalls, warning letters, and import alerts.
Navigating U.S. medical device entry requires an end-to-end strategy. Learn how to position your medical device in the U.S. market while building an audit-ready quality framework.
Understanding 21 CFR Part 820 and the FDA QMSR Transition
The FDA updated 21 CFR Part 820 under the Quality Management System Regulation (QMSR). This amendment explicitly incorporates international standard ISO 13485:2016 by reference into U.S. law, creating a unified global benchmark for medical device quality management.
While the fundamental focus on device safety and CGMP guidelines remains unchanged, the QMSR transition updates legacy terminology and documentation expectations:
Device Master Record (DMR) → Medical Device File (MDF): Legacy DMR files are now structured under the ISO 13485 Medical Device File concept.
Design History File (DHF) → Design and Development File (DDF): Design evolution records map directly to ISO Clause 7.3.
Management Representative → Top Management: Executive leaders share direct, auditable legal responsibility for QMS performance.
Expanded Inspection Scope: FDA investigators now have direct authority to inspect internal quality audits, management reviews, and supplier audit reports during routine inspections.
Understanding the nuances between regional frameworks is critical for global success. Review our breakdown on the differences between FDA 21 CFR Part 820 and ISO 13485 to align your system globally.
Must Read: Difference Between FDA 21 CFR Part 820 and ISO 13485
Key Subparts of 21 CFR Part 820 & ISO 13485 Alignment
The structure of 21 CFR Part 820 establishes governance over every phase of device manufacturing. Below is how traditional subparts align with ISO 13485 principles under the QMSR:
| 21 CFR 820 Subpart | Regulatory Focus | ISO 13485 Equivalent Clause | Compliance Objective |
| Subpart B: QMS Requirements | Executive responsibility, personnel, quality policy | Clause 5 & 6.2 | Define management accountability and staff qualifications. |
| Subpart C: Design Controls | Design planning, inputs, outputs, verification, validation | Clause 7.3 | Ensure device design matches user needs and intended use. |
| Subpart D: Document Controls | Document approval, issuance, change logs | Clause 4.2.4 | Maintain control over quality standard operating procedures (SOPs). |
| Subpart E: Purchasing Controls | Supplier evaluation, purchasing data, raw material approval | Clause 7.4 | Manage supply chain risks and contract manufacturing. |
| Subpart F: Identification & Traceability | UDI integration, material identification | Clause 7.5.8 & 7.5.9 | Trace components and finished devices through distribution. |
| Subpart G: Production & Process Controls | Process validation, equipment calibration, automation | Clause 7.5 | Control manufacturing processes to guarantee consistency. |
| Subpart H: Acceptance Activities | Receiving, in-process, and final inspection | Clause 7.4.3 & 8.2.6 | Validate that materials meet specifications before release. |
| Subpart I: Nonconforming Product | Segregation, evaluation, disposition, rework | Clause 8.3 | Prevent unintended distribution of defective devices. |
| Subpart J: CAPA | Corrective action & preventive action investigations | Clause 8.5.2 & 8.5.3 | Systematically resolve root causes of defects and nonconformities. |
| Subpart K: Labeling & Packaging | Label integrity, UDI printing, packaging validation | Clause 7.5.1 | Prevent labeling mix-ups and protect device sterility. |
| Subpart M: Records | Device History Records (DHR), complaint files | Clause 4.2.5 & 8.2.2 | Maintain complete production audit trails and user complaints. |
Critical Components for 21 CFR Part 820 Compliance
1. Design Controls & Development Execution
For Class II and Class III medical devices (and select Class I devices), Design Controls (Subpart C) require strict governance throughout product development. Manufacturers must establish:
Design Inputs: Clear physical, performance, environmental, and safety requirements.
Design Verification & Validation: Proving through empirical testing that the device meets engineering specifications and satisfies user needs.
Design Transfer: Smoothly transferring design outputs into scalable production specifications.
Integrating compliance early saves millions in potential redesign costs. Explore our specialized services in new product design development and learn more about drafting a compliant Design History File (DHF) or design and development of medical devices.
2. Corrective and Preventive Action (CAPA)
CAPA (Subpart J) remains the most frequently cited area during FDA Form 483 observations and Warning Letters. A robust CAPA framework requires medical device companies to:
Analyze nonconformities across production, complaints, and audits.
Conduct formal Root Cause Analysis (RCA) using 5-Why or Fishbone frameworks.
Validate that corrective actions do not introduce new risks to the device.
Implement systemic changes across SOPs and staff training modules.
3. Recordkeeping & Device History Records
Under Subpart M, manufacturers must maintain an auditable paper or electronic trail for every batch produced. The Device History Record (DHR) verifies that manufacturing followed the exact parameters set in the Medical Device File (MDF).
FDA 21 CFR Part 820 FAQs: Understand U.S. quality system requirements, ISO 13485 alignment, and QMSR compliance rules in our complete guide to 21 CFR Part 820 FAQs for medical devices.
Need expert help establishing or auditing your FDA QMS
Consult with Operon Strategist’s US FDA Compliance Specialists today.
Streamlining 21 CFR Part 820 & QMSR Compliance with Operon Strategist
Building and maintaining a compliant Quality Management System under FDA regulations can be complex, but medical device manufacturers do not have to navigate it alone. Operon Strategist provides end-to-end technical expertise to help companies establish, optimize, and defend their quality frameworks:
Custom QMS Architecture: Designing turnkey Quality Management Systems (QMS) aligned with 21 CFR Part 820 and ISO 13485:2016.
QMSR Transition & Gap Analysis: Upgrading legacy QSR documentation (DMR/DHF) into modern Medical Device Files (MDF) and Design Development Files (DDF).
FDA 510(k) & Regulatory Submissions: Supporting total compliance alongside market clearance via our US FDA (510(k), QMSR, & Registration) services.
Mock FDA Audits & CAPA Remediation: Conducting rigorous pre-inspection audits and resolving FDA 483 observations or Warning Letters.
Global Registration Support: Expanding market access seamlessly via Global Product Registration solutions.
Also Read: 21 CFR Part 11 Compliance for Medical Device Companies
Preparing for an FDA inspection or updating your legacy QSR to QMSR
Schedule a comprehensive regulatory gap analysis with Operon Strategist today.
FAQ's
What is the primary purpose of FDA 21 CFR Part 820?
21 CFR Part 820 establishes Current Good Manufacturing Practice (CGMP) requirements to ensure medical devices designed, manufactured, packaged, or stored in the U.S. are safe and effective.
What is the FDA QMSR transition in relation to 21 CFR 820?
The Quality Management System Regulation (QMSR) amends 21 CFR Part 820 by incorporating ISO 13485:2016 by reference, harmonizing U.S. FDA requirements with international QMS standards.
Which medical devices are subject to Design Controls under 21 CFR 820.30?
All Class II and Class III medical devices, as well as specific Class I devices (such as software-driven devices or automated machinery), are legally required to maintain design controls.
What is the difference between a DHF and a DHR?
The Design History File (DHF) documents the design evolution of the device. The Device History Record (DHR) proves that a specific batch or lot was manufactured in accordance with approved specifications.
How does 21 CFR Part 820 handle supplier management?
Subpart E (Purchasing Controls) requires manufacturers to evaluate, select, and monitor suppliers based on their capability to meet quality specifications through documented agreements and routine audits.